Want to see OMDA full AI Analyst Report?
OMDA Stock Chart & Stats
$14.14
-$4.40(-19.47%)
At close: 4:00 PM EDT
$14.14
-$4.40(-19.47%)
Day’s Range― - ―
52-Week Range$10.28 - $26.92
Previous Close$18.29
Volume2.54M
Average Volume (3M)1.14M
Market Cap
$1.40B
Enterprise Value$813.72M
Total Cash (Recent Filing)$211.76M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.82
Next Earnings
Aug 06, 2026EPS Estimate
0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.11
Shares Outstanding59,448,505
10 Day Avg. Volume1,360,769
30 Day Avg. Volume1,144,096
Financial Highlights & Ratios
PEG Ratio0.97
Price to Book (P/B)4.01
Price to Sales (P/S)3.54
P/FCF Ratio54.46
Enterprise Value/Market Cap0.58
Enterprise Value/Revenue2.87
Enterprise Value/Gross Profit4.34
Enterprise Value/Ebitda1.66K
Forecast
1Y Price Target
$22.89Price Target Upside61.87% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)0.28
Revenue Forecast (FY)$327.31M
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthA debt-free balance sheet with ~$212M of cash provides multi-quarter runway and financial optionality to invest in product, go-to-market, or tuck-in M&A without near-term refinancing risk. This durable liquidity reduces financial risk and supports scaling as unit economics improve.
Scale & Recurring Revenue GrowthRapid membership and revenue growth reflect strong uptake of subscription programs and recurring contracted fees. Member scale improves predictability, drives operating leverage, and supports higher lifetime value per account if retention and multi-condition expansion remain strong.
Clinical Evidence & Channel ExpansionBroad PBM links and inclusion in Optum Rx and Lilly channels expand addressable market and prescribing pathways. Combined with peer‑reviewed clinical evidence and meaningful GLP‑1 care engagement, these durable partnerships enhance competitive positioning and long-term growth optionality.
Bears Say
Remaining GAAP UnprofitabilityDespite margin improvement and narrower losses, GAAP profitability remains negative. Until multi-year positive net income is sustained, equity returns and reinvestment capacity remain constrained, and the company may face pressure to balance growth investment with a path to consistent profitability.
Blended Revenue-per-Member PressureBy-design step-downs in revenue for cohorts in years 2–3 reduce blended ARPU even as margins per member rise. This structural cohort effect requires sustained new enrollment or expansion to maintain top-line growth, creating a durable dependency on continual acquisition and upsell.
Competitive, Multi‑Vendor PBM EnvironmentPlacement in non‑exclusive PBM channels means share gains are contested and may require ongoing pricing, enablement, and evidence differentiation. Over time, multi‑vendor dynamics can compress commercial economics and slow net new revenue unless Omada secures durable differentiation.
Omada Health, Inc. News
OMDA FAQ
What was Omada Health, Inc.’s price range in the past 12 months?
Omada Health, Inc. lowest stock price was $10.28 and its highest was $26.91 in the past 12 months.
What is Omada Health, Inc.’s market cap?
Omada Health, Inc.’s market cap is $1.40B.
When is Omada Health, Inc.’s upcoming earnings report date?
Omada Health, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 26 days.
How were Omada Health, Inc.’s earnings last quarter?
Omada Health, Inc. released its earnings results on May 07, 2026. The company reported $0.04 earnings per share for the quarter, beating the consensus estimate of -$0.128 by $0.168.
Is Omada Health, Inc. overvalued?
According to Wall Street analysts Omada Health, Inc.’s price is currently Undervalued.
Does Omada Health, Inc. pay dividends?
Omada Health, Inc. does not currently pay dividends.
What is Omada Health, Inc.’s EPS estimate?
Omada Health, Inc.’s EPS estimate is 0.07.
How many shares outstanding does Omada Health, Inc. have?
Omada Health, Inc. has 59,448,505 shares outstanding.
What happened to Omada Health, Inc.’s price movement after its last earnings report?
Omada Health, Inc. reported an EPS of $0.04 in its last earnings report, beating expectations of -$0.128. Following the earnings report the stock price went down -9.634%.
Which hedge fund is a major shareholder of Omada Health, Inc.?
Currently, no hedge funds are holding shares in OMDA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Omada Health, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$22.89 (61.87% Upside)
$22.89 (61.87% Upside)
Blogger Sentiment
Neutral
OMDA Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 2.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 6.9%
Last 30 Days ▲ 1.6%
Last 30 Days ▲ 1.6%
Technicals
SMA
Positive
20 days / 200 days
Momentum
29.91%
12-Months-Change
Fundamentals
Return on Equity
-2.81%
Trailing 12-Months
Asset Growth
114.47%
Trailing 12-Months
Company Description
Omada Health, Inc.
Omada Health is an American virtual health company that delivers evidence-based digital programs designed to manage common chronic ailments, including cardiometabolic, musculoskeletal, and behavioral health conditions, offering continuous support that bridges the gap between in-person medical appointments.
OMDA Company Deck
OMDA Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong growth and improving financial health: double-digit revenue growth (42% YoY), a key membership milestone (1.025M members, +51% YoY), margin expansion (GAAP 62%, non-GAAP 64%), positive adjusted EBITDA in Q1 and an upward revision to full-year guidance. Commercial momentum was highlighted by relationships with all three large PBMs and inclusion in Optum Rx and Lilly programs, alongside differentiated clinical evidence for the GLP-1 Care Track. Near-term headwinds are mostly transitional or tactical — cohort composition pressuring blended revenue per member, early-stage nature of some prescribing channels with material revenue expected more in 2027, modest device/shipping cost pressure (~$1M) and competitive multi-vendor PBM environments. Overall, the positives materially outweigh the manageable near-term challenges.View all OMDA earnings summariesOMDA Stock 12 Month Forecast
Average Price Target
$22.89
▲(61.87% Upside)
Technical Analysis
Teladoc
―
American Well
―
GoodRx Holdings
―
Privia Health Group
―
Hinge Health, Inc. Class A
―
Ownership Overview
3.73% Insiders
15.62% Mutual Funds
0.04% Other Institutional Investors
74.28% Public Companies and
Individual Investors